Nasdaq · Healthcare
MYRIAD GENETICS INC (MYGN)
As-reported financials and recent SEC filings for MYRIAD GENETICS INC, latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$824.5M
Net income
$-365.9M
Net margin
-44.4%
Diluted EPS
$-3.95
ROE
-99.4%
P/E (TTM)
—
Market cap
$555.4M
Debt / equity
0.3×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $824.5M | $837.6M | $753.2M | $678.4M | $690.6M |
| Gross profit | $576.6M | $585.4M | $517.0M | $476.4M | — |
| Operating income | $-387.2M | $-123.5M | $-257.4M | $-140.6M | $-190.5M |
| Net income | $-365.9M | $-127.3M | $-263.3M | $-112.0M | $-27.2M |
| Diluted EPS | $-3.95 | $-1.41 | $-3.18 | $-1.39 | $-0.35 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-23
View on EDGAR →8-K2026-06-23
View on EDGAR →42026-06-12
View on EDGAR →42026-06-12
View on EDGAR →42026-06-09
View on EDGAR →1442026-06-08
View on EDGAR →42026-06-05
View on EDGAR →42026-06-05
View on EDGAR →Go deeper on MYGN
Search MYRIAD GENETICS INC’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.